tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Foghorn Therapeutics Reports Q2 2025 Financial Update
PremiumCompany AnnouncementsFoghorn Therapeutics Reports Q2 2025 Financial Update
2M ago
Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)
Premium
The Fly
Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)
2M ago
Foghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence
Premium
Company Announcements
Foghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence
2M ago
Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration
PremiumRatingsFoghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration
4M ago
Foghorn Therapeutics Advances FHD-909 Phase 1 Trial
Premium
Company Announcements
Foghorn Therapeutics Advances FHD-909 Phase 1 Trial
4M ago
Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)
Premium
The Fly
Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)
4M ago
Foghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments
PremiumRatingsFoghorn Therapeutics: Buy Rating Backed by Innovative Oncology Approaches and Promising Clinical Developments
5M ago
Foghorn Therapeutics announces new preclinical data at AACR
Premium
The Fly
Foghorn Therapeutics announces new preclinical data at AACR
5M ago
Foghorn Therapeutics Presents Preclinical Data at AACR 2025
Premium
Company Announcements
Foghorn Therapeutics Presents Preclinical Data at AACR 2025
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100